Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis☆☆☆★★★
Thomas B. Casale(University of South Florida), Robert B. Fick(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jonathan A. Bernstein(Bernstein Clinical Research Center), Robert J. Dockhorn, David G. Tinkelman, Craig LaForce(Children's Hospital Colorado), R Stoltz, James D. Reimann, John Q. Su, William W. Busse(University of Wisconsin–Madison)
Cited by 327
Related Papers
Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines—2016 revision
|Journal of Allergy and Clinical Immunology|2017|2k
An Official American Thoracic Society/European Respiratory Society Statement: Asthma Control and Exacerbations
|American Journal of Respiratory and Critical Care Medicine|2009|1.9k
Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 Revision
|Journal of Allergy and Clinical Immunology|2010|1.8k
The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria
|Allergy|2018|1.5k
Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma
|Journal of Allergy and Clinical Immunology|2001|1.3k